Back to Parexel Insights

Start a conversation
Share this report

Report Home
Empowering Patients
- Democratize the data to advance precision oncology
- Patient Testimonial: Triumphant Testimony to the Power of Precision Oncology
Regulatory Strategies
- Three strategies to meet Project Optimus requirements
- How to find the least burdensome regulatory path for a co-developed CDx
Development Discussions
- How new -omics data and deep learning are accelerating biomarker development for cancer
- Community sites are a win-win for cancer patients and sponsors, but there are some risks to manage
Market Access
- Advancing precision oncology: Expanding patient access to biomarkers and testing capabilities

Report Home
Empowering cancer patients
Regulatory Strategies
Development Discussions
Market Access

Start a conversation
Share this report

Main Menu

Executive Summary

Download the executive summary of the New Medicines, Novel Insights: Advancing Precision Oncology

Download Report

Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers quality solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With Heart™ every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. This approach continues to earn us recognition industrywide, with Parexel being the recipient of the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships, named “Best Contract Research Organization” in November 2023 by an independent panel for Citeline, and “Top CRO to Work With” by investigative sites worldwide in the 2023 and 2024 WCG CenterWatch Global Site Relationship Benchmark Survey. For more information, visit parexel.com.

2520 Meridian Parkway,
Durham, NC 27713
+1 919 544 3170

Privacy Policy
Cookies
Terms of Service
Modern Slavery Statement Act

© 2024. Parexel International (MA) Corporation. All Rights Reserved.

Executive Summary

Executive Summary

Get access now.

Email *

Country *

Success!

Thank you for requesting access. If the page does not reload automatically within ten seconds please refresh to see this exclusive content.

There was an error submitting the form. Please reload and try again.